COVID-19 Impact on Global Personalized Medicine and Epigenomics Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Reagents
  • 1.4.3 Kits
  • 1.4.4 Instruments
  • 1.4.5 Enzymes
  • 1.4.6 Services
• 1.5 Market by Application
  • 1.5.1 Global Personalized Medicine and Epigenomics Market Share by Application: 2020 VS 2026
  • 1.5.2 Oncology
  • 1.5.3 Non-Oncology
  • 1.5.4 Cancer Drug Technology
• 1.6 Coronavirus Disease 2019 (Covid-19): Personalized Medicine and Epigenomics Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Personalized Medicine and Epigenomics Industry
    • 1.6.1.1 Personalized Medicine and Epigenomics Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Personalized Medicine and Epigenomics Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Personalized Medicine and Epigenomics Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Personalized Medicine and Epigenomics Market Perspective (2015-2026)
• 2.2 Personalized Medicine and Epigenomics Growth Trends by Regions
  • 2.2.1 Personalized Medicine and Epigenomics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Personalized Medicine and Epigenomics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Personalized Medicine and Epigenomics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Personalized Medicine and Epigenomics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Personalized Medicine and Epigenomics Players by Market Size
  • 3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2015-2020)
  • 3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Personalized Medicine and Epigenomics Market Concentration Ratio
  • 3.2.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2019
• 3.3 Personalized Medicine and Epigenomics Key Players Head office and Area Served
• 3.4 Key Players Personalized Medicine and Epigenomics Product Solution and Service
• 3.5 Date of Enter into Personalized Medicine and Epigenomics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2015-2020)
• 4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2021-2026)

5 Personalized Medicine and Epigenomics Breakdown Data by Application (2015-2026)

• 5.1 Global Personalized Medicine and Epigenomics Market Size by Application (2015-2020)
• 5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Personalized Medicine and Epigenomics Market Size (2015-2020)
• 6.2 Personalized Medicine and Epigenomics Key Players in North America (2019-2020)
• 6.3 North America Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
• 6.4 North America Personalized Medicine and Epigenomics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Personalized Medicine and Epigenomics Market Size (2015-2020)
• 7.2 Personalized Medicine and Epigenomics Key Players in Europe (2019-2020)
• 7.3 Europe Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
• 7.4 Europe Personalized Medicine and Epigenomics Market Size by Application (2015-2020)

8 China

• 8.1 China Personalized Medicine and Epigenomics Market Size (2015-2020)
• 8.2 Personalized Medicine and Epigenomics Key Players in China (2019-2020)
• 8.3 China Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
• 8.4 China Personalized Medicine and Epigenomics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Personalized Medicine and Epigenomics Market Size (2015-2020)
• 9.2 Personalized Medicine and Epigenomics Key Players in Japan (2019-2020)
• 9.3 Japan Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
• 9.4 Japan Personalized Medicine and Epigenomics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Personalized Medicine and Epigenomics Market Size (2015-2020)
• 10.2 Personalized Medicine and Epigenomics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Personalized Medicine and Epigenomics Market Size by Application (2015-2020)

11 India

• 11.1 India Personalized Medicine and Epigenomics Market Size (2015-2020)
• 11.2 Personalized Medicine and Epigenomics Key Players in India (2019-2020)
• 11.3 India Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
• 11.4 India Personalized Medicine and Epigenomics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Personalized Medicine and Epigenomics Market Size (2015-2020)
• 12.2 Personalized Medicine and Epigenomics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Personalized Medicine and Epigenomics Market Size by Type (2015-2020)
• 12.4 Central & South America Personalized Medicine and Epigenomics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Abbott Laboratories
  • 13.1.1 Abbott Laboratories Company Details
  • 13.1.2 Abbott Laboratories Business Overview and Its Total Revenue
  • 13.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
  • 13.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2015-2020))
  • 13.1.5 Abbott Laboratories Recent Development
• 13.2 Affymetrix
  • 13.2.1 Affymetrix Company Details
  • 13.2.2 Affymetrix Business Overview and Its Total Revenue
  • 13.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
  • 13.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.2.5 Affymetrix Recent Development
• 13.3 Agilent Technologies
  • 13.3.1 Agilent Technologies Company Details
  • 13.3.2 Agilent Technologies Business Overview and Its Total Revenue
  • 13.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
  • 13.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.3.5 Agilent Technologies Recent Development
• 13.4 Astellas Pharmaceuticals
  • 13.4.1 Astellas Pharmaceuticals Company Details
  • 13.4.2 Astellas Pharmaceuticals Business Overview and Its Total Revenue
  • 13.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
  • 13.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.4.5 Astellas Pharmaceuticals Recent Development
• 13.5 BAYER AG
  • 13.5.1 BAYER AG Company Details
  • 13.5.2 BAYER AG Business Overview and Its Total Revenue
  • 13.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
  • 13.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.5.5 BAYER AG Recent Development
• 13.6 Bio Vision
  • 13.6.1 Bio Vision Company Details
  • 13.6.2 Bio Vision Business Overview and Its Total Revenue
  • 13.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
  • 13.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.6.5 Bio Vision Recent Development
• 13.7 Celgene Corp.
  • 13.7.1 Celgene Corp. Company Details
  • 13.7.2 Celgene Corp. Business Overview and Its Total Revenue
  • 13.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
  • 13.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.7.5 Celgene Corp. Recent Development
• 13.8 Emd Millipore
  • 13.8.1 Emd Millipore Company Details
  • 13.8.2 Emd Millipore Business Overview and Its Total Revenue
  • 13.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
  • 13.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.8.5 Emd Millipore Recent Development
• 13.9 Epigenomics AG
  • 13.9.1 Epigenomics AG Company Details
  • 13.9.2 Epigenomics AG Business Overview and Its Total Revenue
  • 13.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
  • 13.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.9.5 Epigenomics AG Recent Development
• 13.10 Epigentex
  • 13.10.1 Epigentex Company Details
  • 13.10.2 Epigentex Business Overview and Its Total Revenue
  • 13.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
  • 13.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 13.10.5 Epigentex Recent Development
• 13.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
  • 10.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
  • 10.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview and Its Total Revenue
  • 10.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
  • 10.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
• 13.12 Gilead Sciences
  • 10.12.1 Gilead Sciences Company Details
  • 10.12.2 Gilead Sciences Business Overview and Its Total Revenue
  • 10.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
  • 10.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.12.5 Gilead Sciences Recent Development
• 13.13 Glaxosmithkline
  • 10.13.1 Glaxosmithkline Company Details
  • 10.13.2 Glaxosmithkline Business Overview and Its Total Revenue
  • 10.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
  • 10.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.13.5 Glaxosmithkline Recent Development
• 13.14 Illumina Inc.
  • 10.14.1 Illumina Inc. Company Details
  • 10.14.2 Illumina Inc. Business Overview and Its Total Revenue
  • 10.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
  • 10.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.14.5 Illumina Inc. Recent Development
• 13.15 Johnson & Johnson
  • 10.15.1 Johnson & Johnson Company Details
  • 10.15.2 Johnson & Johnson Business Overview and Its Total Revenue
  • 10.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
  • 10.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.15.5 Johnson & Johnson Recent Development
• 13.16 Karus Therapeutics Limited
  • 10.16.1 Karus Therapeutics Limited Company Details
  • 10.16.2 Karus Therapeutics Limited Business Overview and Its Total Revenue
  • 10.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
  • 10.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.16.5 Karus Therapeutics Limited Recent Development
• 13.17 Laboratory Corp. Of America Holdings
  • 10.17.1 Laboratory Corp. Of America Holdings Company Details
  • 10.17.2 Laboratory Corp. Of America Holdings Business Overview and Its Total Revenue
  • 10.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
  • 10.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.17.5 Laboratory Corp. Of America Holdings Recent Development
• 13.18 LES Laboratoires Servier
  • 10.18.1 LES Laboratoires Servier Company Details
  • 10.18.2 LES Laboratoires Servier Business Overview and Its Total Revenue
  • 10.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
  • 10.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.18.5 LES Laboratoires Servier Recent Development
• 13.19 Merck
  • 10.19.1 Merck Company Details
  • 10.19.2 Merck Business Overview and Its Total Revenue
  • 10.19.3 Merck Personalized Medicine and Epigenomics Introduction
  • 10.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.19.5 Merck Recent Development
• 13.20 Naturewise Biotech & Medicals Corp.
  • 10.20.1 Naturewise Biotech & Medicals Corp. Company Details
  • 10.20.2 Naturewise Biotech & Medicals Corp. Business Overview and Its Total Revenue
  • 10.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
  • 10.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.20.5 Naturewise Biotech & Medicals Corp. Recent Development
• 13.21 Novartis Pharma AG
  • 10.21.1 Novartis Pharma AG Company Details
  • 10.21.2 Novartis Pharma AG Business Overview and Its Total Revenue
  • 10.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
  • 10.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.21.5 Novartis Pharma AG Recent Development
• 13.22 Oncolys Biopharma Inc.
  • 10.22.1 Oncolys Biopharma Inc. Company Details
  • 10.22.2 Oncolys Biopharma Inc. Business Overview and Its Total Revenue
  • 10.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
  • 10.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.22.5 Oncolys Biopharma Inc. Recent Development
• 13.23 Orchid Chemicals & Pharmaceuticals Limited
  • 10.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
  • 10.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview and Its Total Revenue
  • 10.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
  • 10.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
• 13.24 Progen Pharmaceuticals Limited
  • 10.24.1 Progen Pharmaceuticals Limited Company Details
  • 10.24.2 Progen Pharmaceuticals Limited Business Overview and Its Total Revenue
  • 10.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
  • 10.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.24.5 Progen Pharmaceuticals Limited Recent Development
• 13.25 Quest Diagnostics
  • 10.25.1 Quest Diagnostics Company Details
  • 10.25.2 Quest Diagnostics Business Overview and Its Total Revenue
  • 10.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
  • 10.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.25.5 Quest Diagnostics Recent Development
• 13.26 Roche Holding AG
  • 10.26.1 Roche Holding AG Company Details
  • 10.26.2 Roche Holding AG Business Overview and Its Total Revenue
  • 10.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
  • 10.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.26.5 Roche Holding AG Recent Development
• 13.27 Rubicon Genomics
  • 10.27.1 Rubicon Genomics Company Details
  • 10.27.2 Rubicon Genomics Business Overview and Its Total Revenue
  • 10.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
  • 10.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.27.5 Rubicon Genomics Recent Development
• 13.28 Takeda Pharmaceutical Company Limited
  • 10.28.1 Takeda Pharmaceutical Company Limited Company Details
  • 10.28.2 Takeda Pharmaceutical Company Limited Business Overview and Its Total Revenue
  • 10.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
  • 10.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2015-2020)
  • 10.28.5 Takeda Pharmaceutical Company Limited Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer